上海招聘

Responsibilities:
1.Receive, track, process, and report SAE and AEs of Special Interest cases from clinical trials, within the required timeframe for regulatory reporting and data exchanging with HMP’s partners;
2.Perform the case assessment for completeness, accuracy and legibility; Interpret source documents including relevant medical conditions, lab results and procedures to compile complete and accurate narrative summaries;
3.Produce or review the clinical safety queries as needed for case clarification;
4.Prepare safety periodic reports, e.g. Safety line listings, safety summary, with the required timeline;
5.Interact on a regular basis with contract drug safety vendor (CRO safety team) to resolve safety-related issues in case processing;
6.Be involved in case medical review for seriousness, expectedness, and causality;
7.Be involved in generating and distributing the Safety Notification Letters of SUSARs, Clinical or Pre-clinical Safety Findings;
8.Serve as a Safety Liaison Contact to other functions in clinical development for the assigned clinical projects;
9.Complete the assignments in clinical projects, e.g. Review of safety management plans, safety sections of clinical protocols and CSRs, and others;
10.Others, e.g. SOPs drafting, reviewing and maintenance.

Qualifications:
1.A bachelor degree or above, majored in medicine;
2.1-2 years working experience in pharmacovigilance, clinical research, or medical affairs;
3.Knowledge of ICH/FDA/EMA/CFDA regulations/guidance for pharmacovigilance, and be familiar with GCP;
4.Fluent in both written and spoken English;
5.Good communication skills and computer skills.

和黄中国医药科技有限公司（简称“ 和黄医药 ”或“ Chi-Med ”）（纳斯达克 / 伦交所：HCM）是一家创新型生物医药公司，在过去20年间致力于发现和全球开发治疗癌症和自身免疫性疾病的靶向药物和免疫疗法。目前，和黄医药共有8个抗癌类候选药物正在全球开发中，并在中国本土市场拥有广泛的商业网络。

和黄医药成立于2002年，为在纽约和伦敦两地上市的和黄中国医药科技有限公司（纳斯达克/伦交所： HCM）旗下专注于新药研发业务的子公司, 研发中心坐落在上海浦东张江高科技园区，海外临床开发及注册中心位于美国新泽西，具有完备的研发平台和GMP生产基地。管理团队成员均有在知名跨国医药和生物医药企业工作的经历，参与了多个全球新药研发；公司目前有500余位来自海内外，拥有丰富新药研发经验的科研人员，8大临床在研药物、 30多项临床试验在全球开展。

和黄医药是一家致力于创新药物研发的生物医药公司，专注于发现和开发治疗癌症和自身免疫性疾病的靶向药物和免疫疗法。 自主研发的抗肿瘤新药呋喹替尼已于2018年9月获国家药品监督管理局批准上市，并于2019年11月获纳入国家医保药品目录。公司的其他候选药物，如索凡替尼、沃利替尼等，也已进入后期开发，有望在2020及2021年上市。